Dr. Gabriel A. Brooks
Claim this profileDartmouth Hitchcock Medical Center/Dartmouth Cancer Center
Studies Colorectal Cancer
Studies Colon Cancer
10 reported clinical trials
27 drugs studied
Area of expertise
1Colorectal Cancer
Stage III
Stage IV
BRAF negative
2Colon Cancer
Stage III
Stage IV
BRAF negative
Affiliated Hospitals
Clinical Trials Gabriel A. Brooks is currently running
Chemotherapy vs Chemoradiotherapy
for Rectal Cancer
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limited surgery? If radiation therapy is not given, is quality of life better?
Recruiting2 awards Phase 3
Pembrolizumab + Olaparib
for Pancreatic Cancer
This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. These proteins help repair damaged deoxyribonucleic acid (DNA) and, therefore, play a role in ensuring the stability of each cell's genetic material. When either of these genes is mutated, or altered, such that its protein product is not made or does not function correctly, DNA damage may not be repaired properly. As a result, cells are more likely to develop additional genetic alterations that can lead to some types of cancer, including pancreatic cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Olaparib is an inhibitor of PARP, a protein that helps repair damaged DNA. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of pembrolizumab to the usual treatment of olaparib may help to shrink tumors in patients with metastatic pancreatic cancer with BRCA1 or BRCA2 mutations.
Recruiting1 award Phase 237 criteria
More about Gabriel A. Brooks
Clinical Trial Related7 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Gabriel A. Brooks has experience with
- Oxaliplatin
- Cetuximab
- Capecitabine
- Leucovorin
- 5-FU
- FOX Dose-escalation Algorithm
Breakdown of trials Gabriel A. Brooks has run
Colorectal Cancer
Colon Cancer
Rectal Cancer
Gastroesophageal Junction Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gabriel A. Brooks specialize in?
Gabriel A. Brooks focuses on Colorectal Cancer and Colon Cancer. In particular, much of their work with Colorectal Cancer has involved Stage III patients, or patients who are Stage IV.
Is Gabriel A. Brooks currently recruiting for clinical trials?
Yes, Gabriel A. Brooks is currently recruiting for 5 clinical trials in Lebanon New Hampshire. If you're interested in participating, you should apply.
Are there any treatments that Gabriel A. Brooks has studied deeply?
Yes, Gabriel A. Brooks has studied treatments such as Oxaliplatin, Cetuximab, Capecitabine.
What is the best way to schedule an appointment with Gabriel A. Brooks?
Apply for one of the trials that Gabriel A. Brooks is conducting.
What is the office address of Gabriel A. Brooks?
The office of Gabriel A. Brooks is located at: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire 03756 United States. This is the address for their practice at the Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.